Trials / Recruiting
RecruitingNCT07425483
CAR-NK Cells (CL-NK-003) in Pancreatic Cancer
A Clinical Study of CAR-NK Cells (CL-NK-003) in Patients With Advanced Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.
Detailed description
A fixed-dose study will evaluate the safety, tolerability and efficacy of CAR-NK cells (CL-NK-003) in patients with locally advanced, metastatic, or recurrent pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CL-NK-003 | Fixed-dose (3 × 10\^9 cells) |
Timeline
- Start date
- 2026-02-12
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2026-02-23
- Last updated
- 2026-02-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07425483. Inclusion in this directory is not an endorsement.